Company news
Ascendis Pharma A/s (NASDAQ:ASND) news
Every Ascendis Pharma A/s press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
March 31, 2025
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
February 20, 2025
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
February 12, 2025
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
December 19, 2024
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
December 12, 2024